S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
PURPOSE: This research trial studies DNA in samples from patients with acute myeloid leukemia.
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Other: laboratory biomarker analysis
Other: medical chart review
|Study Design:||Time Perspective: Retrospective|
|Official Title:||S8600-S9031-S9333-A, Identification of Differentially Methylated Genomic Regions That Are Prognostically Significant in AML|
- Identification of DMRs associated with OS [ Time Frame: immediate ] [ Designated as safety issue: No ]
- Development and evaluation of a prognostic score of OS based on DMRs identified [ Time Frame: immediate ] [ Designated as safety issue: No ]
- Prognostic score able to group AML patients into risk groups [ Time Frame: immediate ] [ Designated as safety issue: No ]
|Study Start Date:||October 2011|
|Study Completion Date:||December 2015|
|Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
- To identify differentially methylated regions (DMRs) associated with overall survival (OS) of acute myeloid leukemia (AML) patients with normal cytogenetics.
- To develop and evaluate in an independent validation set a prognostic score for OS based on the identified DMR.
- To determine whether the prognostic score can group patients into risk groups based on OS.
OUTLINE: Archived blood or bone marrow samples are analyzed for DNA methylation alterations by CHARM array-based genome assay. Each patient's clinical data is also collected.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01434329
|Principal Investigator:||Min Fang, MD, PhD||Fred Hutchinson Cancer Research Center|